$PMVP (+3.3% pre) PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors - SI   https://t.co/JC52gcIcTV